Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | QPCT | Q16769 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17482346 | 0.95 | L3MBTL1 (0.60) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4399230 | 0.90 | ALDH1A1 (0.54) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL13655177 | 0.86 | SMN1; SMN2 (0.72) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL18544251 | 0.86 | L3MBTL1 (0.69) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6398857 | 0.85 | L3MBTL1 (0.68) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL18317579 | 0.85 | L3MBTL1 (0.68) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL935331 | 0.84 | L3MBTL1 (0.59) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL14365890 | 0.84 | QPCT (0.68) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL13472650 | 0.84 | KDM4E (0.67) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL18317375 | 0.83 | L3MBTL1 (0.66) | L3MBTL1QPCTSMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107698755-B | Cationic polymer and preparation method and application thereof | 四川大学 | 2021-03-30 | — | — | CN | claimed |
| WO-2006089874-A1 | BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONES | GPC BIOTECH AG (DE) | 2006-08-31 | — | — | WO | claimed |
| EP-0230035-B1 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID CO (US) | 1994-10-12 | — | — | EP | claimed |
| US-11670777-B2 | Thin film forming composition for energy storage device electrodes | NISSAN CHEMICAL CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| WO-2023072974-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021224291-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | MERCK PATENT GMBH (DE) | 2021-11-11 | — | — | WO | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| CN-107698755-B | Cationic polymer and preparation method and application thereof | 四川大学 | 2021-03-30 | — | — | CN | disclosed |
| WO-2018075600-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-2881394-B1 | CONDENSED RING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-20170239259-A1 | ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1343505-A1 | CXCR3 ANTAGONISTS | Tularik Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002083143-A1 | CXCR3 ANTAGONISTS | TULARIK INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0424214-A1 | 5-[2-[[2-Amino-2-oxoethyl]methylamino]ethyl]-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5(5H)-benzothiazepine-4-one derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | L3MBTL1 1326/4885QPCT 3367/4885SMN1; SMN2 3178/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | L3MBTL1 3931/4885QPCT 417/4885SMN1; SMN2 4399/4885 |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | CYP1A1, NAT1, AKR7A2 | L3MBTL1 2790/4885QPCT 2237/4885SMN1; SMN2 3126/4885 |
| US-20170239259-A1 | ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | HIF1A, HIF1AN, VHL | L3MBTL1 3786/4885QPCT 4688/4885SMN1; SMN2 2399/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | L3MBTL1 2675/4885QPCT 2589/4885SMN1; SMN2 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.